NCT04235205 - Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease | Biotech Hunter

Enrollment

102

Participants

Timeline

Start Date

January 29, 2020

Primary Completion Date

July 21, 2021

Study Completion Date

September 30, 2021

Conditions

Nonalcoholic Fatty LiverNonalcoholic Steatohepatitis

Interventions

DRUG

Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g)

Patients with nonalcoholic fatty liver disease are administered Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g) for 16 weeks

DRUG

Elobixibat 10mg + cholestyramine powder placebo

Patients with nonalcoholic fatty liver disease are administered Elobixibat 10mg+ cholestyramine powder placebo for 16 weeks

DRUG

Elobixibat placebo + cholestyramine powder 9g (cholestyramine 4g)

Patients with nonalcoholic fatty liver disease are administered Elobixibat placebo+ cholestyramine powder 9g (cholestyramine 4g) for 16 weeks

DRUG

Elobixibat placebo + cholestyramine powder placebo

Patients with nonalcoholic fatty liver disease are administered Elobixibat placebo+ cholestyramine powder placebo for 16 weeks

Trial Locations (1)

Yokohama City University, Yokohama

All Listed Sponsors

collaborator

EA Pharma Co., Ltd.

INDUSTRY

lead

Yokohama City University

OTHER